RA0164

antibody from Oursmab

Targeting: CTLA4 CD, CD152, CELIAC3, CTLA-4, GSE, IDDM12

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0164

Provider

Oursmab

Product name

Botensilimab (Biosimilar Reference Antibody) (CTLA4)

Antibody type

Monoclonal

Description

Botensilimab is a next-generation, Fc-enhanced cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor. It is engineered to not only block the CTLA-4 immune checkpoint like first-generation inhibitors (e.g., ipilimumab) but also to incorporate an Fc domain modified to enhance binding to activating Fc gamma receptors (Fc¦ÃRs). This design aims to selectively deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment via antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), while simultaneously providing enhanced co-stimulation to effector T cells. It is being investigated in clinical trials (Phase I/II) for the treatment of immunologically "cold" or treatment-refractory advanced solid tumors, both as a monotherapy and in combination with other agents, with the goal of inducing deeper and more durable responses.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.